

- **Name:** Omali Pitiyarachchi
 - **Current Position & Affiliation:** School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney.
Staff Specialist Medical Oncologist, Sunshine Coast University Hospital, Australia.
 - **Country:** Australia
-

• **Educational Background:**

UNSW Sydney – PhD*

Supervisors: Prof. Phoebe Phillips, Prof. David Goldstein, Prof. Michael Friedlander
Lowy Cancer Research Centre, School of Biomedical Sciences, Faculty of Medicine and Health

- National Health and Medical Research Council (NHMRC) Postgraduate Scholarship (2023-2025)
- Maridulu Budyari Gumal (SPHERE) Cancer Clinical Academic Group PhD Scholarship Top-Up Award (2022-2025)
- University Postgraduate Award (2022)

The Royal Australasian College of Physicians – Fellowship

The University of Sydney - Graduate Certificate in Clinical Trials & Research

The University of Sydney - Bachelor of Medicine/Bachelor of Surgery (MBBS)

The University of Sydney - Bachelor of Advanced Science, Major: Neuroscience

• **Professional Experience: (*Current appointments*)**

Medical Oncologist (Staff Specialist), Sunshine Coast University Hospital, Australia (2025-current)

Medical Oncologist (VMO), Prince of Wales Private Hospital, Randwick, Australia (2022-current)

Medical Oncologist (Locum VMO), Chris O'Brien Lifehouse, Camperdown, Australia (2023-current)

• **Professional Organizations:**

European Society for Medical Oncology (ESMO) - Member 2019-current

ESMO Leaders Generation Programme Asia 2023-2024

Medical Oncology Group of Australia (MOGA) - Member (2019-current)

MOGA Workforce and Workload committee (2025-current)

Co-convenor of the Immuno-oncology Symposium (2021)

Australia New Zealand Gynaecological Oncology Group (ANZGOG) - Member (2019-current)

Diversity, Equity and Inclusion Reference Committee (2024-current)

Ovarian Tumour Working Group (2022-current)

ANZGOG 2026 ASM Committee (2025-current)

Australasian Gastro-Intestinal Trials Group (AGITG) - Member (2019- current)

AGITG Medical Oncology Sub-Committee member (2022-current)

• **Main Scientific Publications: (*Selected publications, past 2 years*)**

Textbook chapter

Pitayarachchi, O., Kokkinos, J., Sharbeen, G., Phillips, P.A., Moses, D., Gandy, R.C., Haghighi K.S., Thompson, S.R., Borbassi, J.A.L., Strutt, R., Goldstein, D., “Management of Primary Pancreatic Cancer”, in *Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach, 2nd Edition*, Wiley, 2024 [Invited].

Journal publications

- Chiang, S^{*}, Garcia Netto^{*}, K., Kokkinos, J.^{*}, Haghighi, K.S., Raina, A.S., Youkhana, A., **Pitayarachchi, O.**, Truong, Q., Wenholz, D., Wilkinson, J., Laczka, O., Li, Ziang, Aldilla, V.R., Kumar, N., Goldstein, D., Sharbeen[#], Phillips, P.A.[#], “CRO-67 has anti-cancer activity in pancreatic tumor cells and stromal cancer-associated fibroblasts”. *Sci Rep* 15, 24488 (2025). <https://doi.org/10.1038/s41598-025-09411-2>
- Pitayarachchi, O.**, and Friedlander, M., “Age disparities in clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with high grade serous ovarian cancer: a wake up call to improving outcomes in older patients”, *J Geriatr Oncol*, (2025). <http://dx.doi.org/10.1016/j.jgo.2024.102152>
- Pitayarachchi, O.**, and Tan, A.C., “Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC)”, *Transl Lung Cancer Res*, 14(2): 314-322 (2025). <http://dx.doi.org/10.21037/tlcr-24-968>
- Pitayarachchi, O.**, Ansell, P.J., Coleman, R.L., Dinh M.H., Holman, L., Leath III, C.A., Werner, T., DiSilvestro, P., Morgan, M., Tew, W., Lee, C., Cunningham, M., Newton, M., Edraki, B., Lim, P., Barlin, J., Spirtos, N.M., Tewari, K.S., Edelson, M., Reid, T., Carlson, J., and Friedlander, M., “Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over”, *Gynecol Oncol*, 187:221-226 (2024) <http://dx.doi.org/10.1016/j.ygyno.2024.05.021>
- Pitayarachchi, O.**, Lee, Y.C., Sim, H-W, Srirangan, S., Mapagu, C., Kirk, J., Harnett, P.R., Balleine, R.L., Bowtell, D.D.L., Samimi, G., Brand, A.H., Marsh, D.J., Beale, P., Anderson, L., Bouantoun, N., Provan, P., for the INOVATe Investigators, Ramus, S.J., DeFazio, A., and Friedlander, M., “Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma”, *Transl Oncol*, 31: 101638(2023) <http://dx.doi.org/10.1016/j.tranon.2023.101638>
- Pitayarachchi, O.**, Friedlander, M., Java, J.J., Chan, J.K, Armstrong D.K., Markman, M., Herzog, T.J., Monk, B.J., Backes, F., Alvarez Secord, A., Bonebrake,

A., Rose, P.G., Tewari, T.S., Lentz, S.S., Geller, M.A., Copeland, L.J., and Mannel, R.S., “What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer”, *Gynecol Oncol*, 166(3):410-416(2022)

<https://doi.org/10.1016/j.ygyno.2022.07.004>

- **Pitayarachchi, O.**, Phillips, K.A., and Friedlander, M., “Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation”, *Cancer Treat Res Commun*, 30: 100504(2022). <https://doi.org/10.1016/j.ctarc.2021.100504>
- **Pitayarachchi, O.**, Wong, W., and Chin, M., “Response to durvalumab and multimodality therapy in a patient with multiple recurrent and unresectable cutaneous squamous cell carcinoma”, *Intern Med J*, 52(6):1103-1104(2022). <https://doi.org/10.1111/imj.15809>
- Kokkinos, J.,...+7..., Goldstein, D., Gebski, V., Pajic, M., **Pitayarachchi O.**, +16, Phillips, P., “ β III-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer”, Preprint <https://doi.org/10.1101/2022.09.29.510034>
- Mizrahi, D., Goldstein, D., ..., **Pitayarachchi, O.**, ..., Grimison, P., Boyle, F., and Park, S.B., “Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy”, *Support Care Cancer* 30: 5965-5974(2022). <https://doi.org/10.1007/s00520-022-07024-3>